Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21315647 | 0.99 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21315681 | 0.96 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29961410 | 0.96 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21315645 | 0.94 | MTNR1A (0.54) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29961789 | 0.82 | MAPT (0.54) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21315684 | 0.82 | MAPT (0.54) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29961819 | 0.81 | MAPT (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21315673 | 0.81 | MAPT (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21315658 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1B | |
| SCHEMBL21315660 | 0.79 | MAPT (0.52) | MTNR1AMTNR1BALDH1A1NQO2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741760-B1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-12-04 | — | — | EP | disclosed |
| EP-3529234-B1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2023-11-29 | — | — | EP | disclosed |
| CN-115181108-A | Compound and preparation method, pharmaceutical composition and application thereof | 艾奇实验室制药有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-110088092-B | Compounds, processes for their preparation, pharmaceutical compositions, uses of compounds and methods for treating psychiatric and/or sleep disorders | 艾奇实验室制药有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11091445-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2021-08-17 | — | — | US | disclosed |
| EP-3741760-A1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | Aché Laboratórios Farmacêuticos S.A. (BR) | 2020-11-25 | — | — | EP | disclosed |
| US-10781182-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2020-09-22 | — | — | US | disclosed |
| US-20200277265-A1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2020-09-03 | — | — | US | disclosed |
| US-20190270711-A1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270711-A1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | MTNR1A, MTNR1B, PER2 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 1194/4885 |
| US-20200277265-A1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | MTNR1A, MTNR1B, PER2 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 1214/4885 |
| US-10781182-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | MTNR1A, MTNR1B, PER2 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 1194/4885 |
| US-11091445-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | MTNR1A, MTNR1B, PER2 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.